Search details
1.
Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
Cancer
; 125(21): 3738-3748, 2019 11 01.
Article
in English
| MEDLINE | ID: mdl-31287557
2.
Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer.
J Transl Med
; 16(1): 328, 2018 11 26.
Article
in English
| MEDLINE | ID: mdl-30477533
3.
Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.
Lancet Oncol
; 15(1): e42-50, 2014 Jan.
Article
in English
| MEDLINE | ID: mdl-24384493
4.
Chromosomal 3q amplicon encodes essential regulators of secretory vesicles that drive secretory addiction in cancer.
J Clin Invest
; 2024 Apr 25.
Article
in English
| MEDLINE | ID: mdl-38662435
5.
Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer.
J Thorac Cardiovasc Surg
; 167(4): 1444-1453.e4, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-37816395
6.
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors.
Science
; 381(6662): eabn4180, 2023 09 08.
Article
in English
| MEDLINE | ID: mdl-37676964
7.
Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.
Nat Med
; 29(3): 593-604, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36928818
8.
Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
JTO Clin Res Rep
; 3(11): 100420, 2022 Nov.
Article
in English
| MEDLINE | ID: mdl-36389133
9.
Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer.
J Thorac Cardiovasc Surg
; 164(5): 1327-1337, 2022 11.
Article
in English
| MEDLINE | ID: mdl-35190177
10.
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.
Blood Adv
; 6(3): 891-901, 2022 02 08.
Article
in English
| MEDLINE | ID: mdl-34861697
11.
Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
Clin Cancer Res
; 28(11): 2461-2473, 2022 06 01.
Article
in English
| MEDLINE | ID: mdl-35394499
12.
Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
Lung Cancer
; 154: 76-83, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33631448
13.
Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
J Thorac Oncol
; 16(8): 1289-1297, 2021 08.
Article
in English
| MEDLINE | ID: mdl-33857666
14.
Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.
Eur J Cardiothorac Surg
; 59(1): 100-108, 2021 01 04.
Article
in English
| MEDLINE | ID: mdl-32864702
15.
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
Nat Commun
; 12(1): 5045, 2021 08 19.
Article
in English
| MEDLINE | ID: mdl-34413300
16.
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
Nat Med
; 27(3): 504-514, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33603241
17.
Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
Clin Lung Cancer
; 21(4): 341-348, 2020 07.
Article
in English
| MEDLINE | ID: mdl-32279936
18.
Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells.
Oncogene
; 39(4): 801-813, 2020 01.
Article
in English
| MEDLINE | ID: mdl-31554935
19.
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.
Am J Cancer Res
; 10(12): 4464-4475, 2020.
Article
in English
| MEDLINE | ID: mdl-33415011
20.
EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer.
Nanomedicine (Lond)
; 14(17): 2315-2338, 2019 09.
Article
in English
| MEDLINE | ID: mdl-31432749